The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor–positive advanced breast cancer, reported Hortobagyi et al at the 2016 European Society for Medical Oncology (ESMO) Congress in Copenhagen (Abstract LBA1_PR).
The first interim analysis of data from the randomized, double-blind MONALEESA2 study showed a 44% improvement in progression-free survival with ribociclib plus letrozole as a first-line treatment combination.
“This was the definitive study to demonstrate the superiority of the combination of ribociclib and letrozole over letrozole alone,” said principal investigator Gabriel Hortobagyi, MD, FACP, Nellie B. Connally Chair in Breast Cancer, Program Director of the Susan G. Komen Interdisciplinary Breast Fellowship, and Professor of Medicine at The University of Texas MD Anderson Cancer Center.
Researchers randomized 668 postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer who had not undergone any prior systemic treatment to ribociclib (600 mg/d, 3 weeks on/1 week off) and letrozole (2.5 mg/d, continuous) or letrozole plus placebo.
In the ribociclib arm, there was a 44% improvement in the primary objective of progression-free survival compared to the placebo arm (hazard ratio [HR] = 0.556, P = .00000329). Median progression-free survival was 14.7 months in the placebo arm but was not reached in the ribociclib arm at data cutoff.
“The results of this trial represent a compelling proof of principle and suggest a paradigm shift in metastatic hormone receptor–positive breast cancer. They also suggest that testing combinations of ribociclib with other inhibitors of various signaling pathways might lead to additional progress in the management of several subtypes of breast cancer,” said Dr. Hortobagyi.
Patients with measurable disease at baseline showed a significantly higher objective response rate to ribociclib plus letrozole compared to letrozole alone (53% vs 37%; P = .00028), and improved clinical benefit rate (80% vs 72%; P = .02).
Serious adverse events occurred in fewer than 5% of patients in both arms, but other adverse events were significantly more common in the ribociclib arm. Neutropenia occurred in 59% of patients in the ribociclib arm compared to 1% of the placebo arm; leukopenia occurred in 21% vs 1%; lymphopenia in 7% vs 1%. Patients in the ribociclib arm had a higher incidence of elevated alanine aminotransferase and elevated aspartate aminotransferase.
The number of deaths in the study was too low to enable a reliable analysis of the impact of ribociclib therapy on overall survival.
Commenting on the findings, Giuseppe Curigliano, MD, PhD, Director of the New Drugs and Early Drug Development for Innovative Therapies Division at the European Institute of Oncology, Milan, Italy, said, “I believe the results of this study are significant because now we have a new CDK4/6 inhibitor for patients with estrogen receptor–positive metastatic breast cancer, in addition to palbociclib (Ibrance, already U.S. Food and Drug Administration–approved) and abemaciclib (under development).”
“The addition of ribociclib to letrozole does increase the rate of toxicity, but overall, if we evaluate the magnitude of clinical benefit, there is definitely a benefit to be gained from adding ribociclib.”
Dr. Curigliano also suggested that further studies of ribociclib should examine the use of cancer biomarkers to better identify patients who would respond to the combination.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
Our team is comprised of Bob and Linda Carey, our advisors and volunteers. Without them, changing lives one smile at a time would never be possible!